Rapamycin alleviates toxicity of different aggregate-prone proteins
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Many neurodegenerative diseases are caused by intracellular, aggregate-prone proteins, including polyglutamine-expanded huntingtin in Huntington's disease (HD) and mutant tau in fronto-temporal dementia/tauopathy. Previously, we showed that rapamycin, an autophagy inducer, enhances mutant huntingtin fragment clearance and attenuated toxicity. Here we show much wider applications for this approach. Rapamycin enhances the autophagic clearance of different proteins with long polyglutamines and a polyalanine-expanded protein, and reduces their toxicity. Rapamycin also reduces toxicity in Drosophila expressing wild-type or mutant forms of tau and these effects can be accounted for by reductions in insoluble tau. Thus, our studies suggest that the scope for rapamycin as a potential therapeutic in aggregate diseases may be much broader than HD or even polyglutamine diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“functional autophagy is required to degrade soluble and aggregated variants of MAPT/tau (Berger et al, 2006; Silva et al, 2020).”
From Autophagy in major human diseases (2021) · cites this paper as Berger et al, 2006
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of tau species (including tau lacking phosphorylation at Ser262/356) are degraded by the proteasome [20], while aggregated tau or tau phosphorylated at Ser262/356 is degraded by the autophagy-lysosome system [79–84].”
From Stabilization of Microtubule-Unbound Tau via Tau Phosphorylation at Ser262/356 by Par-1/MARK Contributes to Augmentation of AD-Related Phosphorylation and Aβ42-Induced Tau Toxicity (2016) · cites this paper as [83]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Autophagy as a Regulated Pathway of Cellular Degradation
Klionsky, D. J., & Emr, S. D. (2000) · Science · doi:10.1126/science.290.5497.1717 · Cited by 3,608
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Ravikumar, B., Vacher, C., Berger, Z., Davies, J. E., Luo, S., Oroz, L. G., Scaravilli, F., Easton, D. F., Duden, R., O'Kane, C. J., et al. (2004) · Nature Genetics · doi:10.1038/ng1362 · Cited by 2,347 · cited 4×
“Because rapamycin is designed for long-term use and crosses the blood–brain barrier (17), it merits consideration for further studies in a range of neuroprotective contexts.”
BackgroundResultInfluentialSelf-citationConversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration
Patrick, G. N., Zukerberg, L., Nikolic, M., de la Monte, S., Dikkes, P., & Tsai, L.-H. (1999) · Nature · doi:10.1038/45159 · Cited by 1,545
α-Synuclein Is Degraded by Both Autophagy and the Proteasome
Webb, J. L., Ravikumar, B., Atkins, J., Skepper, J. N., & Rubinsztein, D. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300227200 · Cited by 1,429
Self-citationLewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., Gwinn-Hardy, K., Murphy, M. P., Baker, M., Yu, X., et al. (2000) · Nature Genetics · doi:10.1038/78078 · Cited by 1,371 · cited 2×
“Further tests in mouse models of the disorders associated with these aggregate-prone proteins (34,36,37) will be necessary to confirm the beneficial effects of rapamycin or its analogues.”
BackgroundThe tor pathway: a target for cancer therapy
Bjornsti, M.-A., & Houghton, P. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1362 · Cited by 1,314
Tor, a Phosphatidylinositol Kinase Homologue, Controls Autophagy in Yeast
Noda, T., & Ohsumi, Y. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.7.3963 · Cited by 1,309
Toxic Proteins in Neurodegenerative Disease
Taylor, J. P., Hardy, J., & Fischbeck, K. H. (2002) · Science · doi:10.1126/science.1067122 · Cited by 1,251
Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy
Ravikumar, B. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.9.1107 · Cited by 1,111
Self-citation
Cited by
Items 101–140 of 140
Degradation of tau protein by autophagy and proteasomal pathways
Wang, Y., & Mandelkow, E. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120071 · Cited by 166
Small molecule enhancers of autophagy for neurodegenerative diseases
Sarkar, S., & Rubinsztein, D. C. (2008) · Molecular BioSystems · doi:10.1039/b804606a · Cited by 163
Self-citationSilva, M. C., Nandi, G. A., Tentarelli, S., Gurrell, I. K., Jamier, T., Lucente, D., Dickerson, B. C., Brown, D. G., Brandon, N. J., & Haggarty, S. J. (2020) · Nature Communications · doi:10.1038/s41467-020-16984-1 · Cited by 157
Lysosome biogenesis in health and disease
Bajaj, L., Lotfi, P., Pal, R., Ronza, A. D., Sharma, J., & Sardiello, M. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14564 · Cited by 153
“Alzheimer’s, Parkinson’s and Huntington’s diseases and frontotemporal lobar degeneration have consistently shown improved pathology upon mTORC1 pharmacological inhibition with rapamycin/rapalogs (Ravikumar et al. 2004; Berger et al. 2006; Santini et al. 2009; Caccamo et al. 2010; Wang et al. 2012).”
BackgroundCell “Self‐Eating” (Autophagy) Mechanism in Alzheimer's Disease
Funderburk, S. F., Marcellino, B. K., & Yue, Z. (2010) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20161 · Cited by 139
Autophagy and misfolded proteins in neurodegeneration
Metcalf, D. J., García-Arencibia, M., Hochfeld, W. E., & Rubinsztein, D. C. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2010.11.003 · Cited by 138
“Our studies have established that rapamycin treatment enhances the clearance of mutant huntingtin fragments, reduces aggregate formation and protects against toxicity in cell, Drosophila and mouse models of Huntington's disease (HD) (Berger et al., 2006; Ravikumar et al., 2006; Sarkar et al., 2009;Webb et al., 2003).”
BackgroundInfluentialSelf-citationNeely, K. M., Green, K. N., & LaFerla, F. M. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5156-10.2010 · Cited by 134
Protein misfolding disorders and macroautophagy
Menzies, F. M., Moreau, K., & Rubinsztein, D. C. (2011) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2010.10.010 · Cited by 129
“Clearance by autophagy has been demonstrated for both wild-type and mutant forms of tau [58], mutant forms of a-synuclein that cause familial Parkinson’s disease [60] and a range of polyglutamine-expanded proteins [14,57,58,61].”
BackgroundSelf-citationMicroglial-to-neuronal CCR5 signaling regulates autophagy in neurodegeneration
Festa, B. P., Siddiqi, F. H., Jimenez-Sanchez, M., Won, H., Rob, M., Djajadikerta, A., Stamatakou, E., & Rubinsztein, D. C. (2023) · Neuron · doi:10.1016/j.neuron.2023.04.006 · Cited by 129
Self-citationXue, X., Wang, L.-R., Sato, Y., Jiang, Y., Berg, M., Yang, D.-S., Nixon, R. A., & Liang, X.-J. (2014) · Nano Letters · doi:10.1021/nl501839q · Cited by 125
Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets
Lee, V. M.-Y., Brunden, K. R., Hutton, M., & Trojanowski, J. Q. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006437 · Cited by 122
“Macroautophagy can be induced with the drug rapamycin, and treatment of flies expressing wild-type or mutant human tau with rapamycin led to a diminution of insoluble tau (Berger et al. 2006).”
BackgroundThe Role of Tau Oligomers in the Onset of Alzheimer's Disease Neuropathology
Cárdenas-Aguayo, M. D. C., Gómez-Virgilio, L., DeRosa, S., & Meraz-Ríos, M. A. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500148z · Cited by 120
King, M. A., Hands, S., Hafiz, F., Mizushima, N., Tolkovsky, A. M., & Wyttenbach, A. (2008) · Molecular Pharmacology · doi:10.1124/mol.107.043398 · Cited by 120
Alzheimer's Disease Mechanisms and Emerging Roads to Novel Therapeutics
Sala Frigerio, C., & De Strooper, B. (2016) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070815-014015 · Cited by 116
“Inhibition of mechanistic target of rapamycin (mTOR) by rapamycin and its analogs results in increased autophagy and reduction of tau aggregates (Berger et al. 2006, Frederick et al. 2014).”
Oxidant Stress and Signal Transduction in the Nervous System with the PI 3-K, Akt, and mTOR Cascade
Maiese, K., Chong, Z. Z., Wang, S., & Shang, Y. C. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131113830 · Cited by 109
“protein [273], attenuate huntingtin accumulation and cell death in cell models of HD, and protect against neurodegeneration in a fly model of HD [274].”
BackgroundAndo, K., Maruko-Otake, A., Ohtake, Y., Hayashishita, M., Sekiya, M., & Iijima, K. M. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1005917 · Cited by 105
Silva, M. C., Cheng, C., Mair, W., Almeida, S., Fong, H., Biswas, M. H. U., Zhang, Z., Huang, Y., Temple, S., Coppola, G., et al. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.08.001 · Cited by 103
Wang, L., Bharti, Kumar, R., Pavlov, P. F., & Winblad, B. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112915 · Cited by 92
Gentry, E. G., Henderson, B. W., Arrant, A. E., Gearing, M., Feng, Y., Riddle, N. C., & Herskowitz, J. H. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.2336-15.2016 · Cited by 90
“…can be pharmacologically induced with rapamycin through the inhibition of mammalian target of rapamycin (mTOR), and treatment with rapamycin reduced insoluble tau levels in Drosophila models of tauopathy (Berger et al., 2006; Received June 18, 2015; revised Dec. 14, 2015; accepted Dec. 18, 2015.”
BackgroundThe toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics
Pritchard, S. M., Dolan, P. J., Vitkus, A., & Johnson, G. V. W. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01273.x · Cited by 89
“In cell models, rapamycin mediates the reduction of aggregates composed of both polyglutamine and polyalanine expansions [157, 158].”
BackgroundJänen, S. B., Chaachouay, H., & Richter‐Landsberg, C. (2010) · Glia · doi:10.1002/glia.21047 · Cited by 87
Using Human iPSC-Derived Neurons to Model TAU Aggregation
Verheyen, A., Diels, A., Dijkmans, J., Oyelami, T., Meneghello, G., Mertens, L., Versweyveld, S., Borgers, M., Buist, A., Peeters, P., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0146127 · Cited by 86
Chapter 5 Autophagic Clearance of Aggregate‐Prone Proteins Associated with Neurodegeneration
Sarkar, S., Ravikumar, B., & Rubinsztein, D. C. (2009) · Methods in Enzymology · doi:10.1016/s0076-6879(08)04005-6 · Cited by 79
Self-citationRapamycin decreases tau phosphorylation at Ser214 through regulation of cAMP-dependent kinase.
Liu, Y., Su, Y., Wang, J., Sun, S., Wang, T., Qiao, X., Run, X., Li, H., & Liang, Z. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.01.014 · Cited by 64
“However, the rapamycin-induced autophagy may preferentially reduce the hyperphosphorylated and insoluble tau, because the soluble tau is dispersed throughout the cells and may not be readily accessible to autophagic degradation (Berger et al., 2006).”
BackgroundMallucci, G. R., Klenerman, D., & Rubinsztein, D. C. (2020) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-040320-120625 · Cited by 62
Self-citationUBE4B, a microRNA-9 target gene, promotes autophagy-mediated Tau degradation
Subramanian, M., Hyeon, S. J., Das, T., Suh, Y. S., Kim, Y. K., Lee, J.-S., Song, E. J., Ryu, H., & Yu, K. (2021) · Nature Communications · doi:10.1038/s41467-021-23597-9 · Cited by 62
Recent progress in the role of autophagy in neurological diseases
Meng, T., Lin, S., Zhuang, H., Huang, H., He, Z., Hu, Y., Gong, Q., & Feng, D. (2019) · Cell Stress · doi:10.15698/cst2019.05.186 · Cited by 58
The Implications of Autophagy in Alzheimer’s Disease
Hamano, T., Hayashi, K., Shirafuji, N., & Nakamoto, Y. (2018) · Current Alzheimer Research · doi:10.2174/1567205015666181004143432 · Cited by 57
Lee, H.-K., Kwon, B., Lemere, C. A., de la Monte, S., Itamura, K., Ha, A. Y., & Querfurth, H. W. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-161029 · Cited by 57
“Our finding that rapamycin in beneficial (regardless of mTOR basal activation status) is consistent with results that mTOR inhibition ameliorates cognitive deficits and pathology in AD mice [44,46] and disease manifestations and proteotoxicity in other neurodegenerative models [97, 98].”
Autophagy in Alzheimer’s disease
Moreira, P. I., Santos, R. X., Zhu, X., Lee, H.-G., Smith, M. A., Casadesus, G., & Perry, G. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.84 · Cited by 55
Rho Kinase and Dopaminergic Degeneration: A Promising Therapeutic Target for Parkinson’s Disease
Labandeira-Garcia, J. L., Rodríguez-Perez, A. I., Villar-Cheda, B., Borrajo, A., Dominguez-Meijide, A., & Guerra, M. J. (2015) · The Neuroscientist · doi:10.1177/1073858414554954 · Cited by 54
Panda, P. K., Fahrner, A., Vats, S., Seranova, E., Sharma, V., Chipara, M., Desai, P., Torresi, J., Rosenstock, T., Kumar, D., et al. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00038 · Cited by 50
“Stimulating autophagy with mTOR inhibitors like rapamycin or its analogs had beneficial effects in fly and mouse models of Huntington’s disease, Alzheimer’s disease (AD), Parkinson’s disease (PD), frontotemporal dementia (FTD), spinocerebellar ataxia type 3 (SCA3) and prion disease (Ravikumar et al., 2004; Berger et a…”
BackgroundInhibition of lysosomal functions reduces proteasomal activity
Qiao, L., & Zhang, J. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.03.085 · Cited by 50
Protective roles for induction of autophagy in multiple proteinopathies
Menzies, F. M., Ravikumar, B., & Rubinsztein, D. C. (2006) · Autophagy · doi:10.4161/auto.2696 · Cited by 45
Self-citationSpinocerebellar ataxias caused by polyglutamine expansions: A review of therapeutic strategies
Underwood, B. R., & Rubinsztein, D. C. (2008) · The Cerebellum · doi:10.1007/s12311-008-0026-z · Cited by 44
“and in flies with isolated expanded polyQs ( 19 ) and therefore may extrapolate to other CAG repeat spinocerebellar ataxias.”
BackgroundSelf-citationJu, J.-S., Miller, S. E., Jackson, E., Cadwell, K., Piwnica-Worms, D., & Weihl, C. C. (2009) · Autophagy · doi:10.4161/auto.5.4.7761 · Cited by 41
A new method to measure autophagy flux in the nervous system
Matus, S., Valenzuela, V., & Hetz, C. (2014) · Autophagy · doi:10.4161/auto.28434 · Cited by 29
Rapamycin prevents the mutant huntingtin-suppressed GLT-1 expression in cultured astrocytes
Chen, L.-L., Wu, J.-C., Wang, L.-H., Wang, J., Qin, Z.-H., Difiglia, M., & Lin, F. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.162 · Cited by 26
“It was reported that enhancing autophagy with rapamycin treatment increased mutant huntingtin clearance and decreased the levels of soluble proteins and aggregates in HD cell models [11] .”
Roth, J. R., Moraes, R. C. M. D., Xu, B. P., Crawley, S. R., Khan, M. A., & Melkani, G. C. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1223911 · Cited by 16
Protein kinase inhibitors as therapeutics in neurodegenerative and psychiatric disorders
Tridente, G., Jana, A., Nath, A., & Ashraf, G. M. (2023) · Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders · doi:10.1016/b978-0-443-18677-6.00015-4 · Cited by 8
Metadata
- Authors
- Berger, Z., Ravikumar, B., Menzies, F. M., Oroz, L. G., Underwood, B. R., Pangalos, M. N., Schmitt, I., Wullner, U., Evert, B. O., O'Kane, C. J., & Rubinsztein, D. C.
- Affiliations
- University of Cambridge (GB)
- West Suffolk Hospital (GB)
- University Hospital Bonn (DE)
- Corresponding author
- Berger, Zdenek
- ORCID
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-12-20
- Volume
- 15
- Issue
- 3
- Pages
- 433-442
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2098077028
- Cited by
- 657
- References
- 50
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 16 · 2023: 21 · 2022: 22 · 2021: 35 · 2020: 35 · 2019: 25 · 2018: 28 · 2017: 31 · 2016: 31 · 2015: 35 · 2014: 36 · 2013: 35 · 2012: 55
- FWCI
- 10.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Human Molecular Genetics (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Wellcome Trust
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- rapamycin, protein aggregation, neurodegenerative diseases, autophagy, huntingtin, polyglutamine expansion, tau protein, frontotemporal dementia, polyalanine expansion, protein clearance, Drosophila
- MeSH terms
- Animals, Autophagy, Cells, Cultured, Chlorocebus aethiops, Drosophila, Huntington Disease, Mutation, Peptides, Proteins, tau Proteins, COS Cells, Trinucleotide Repeat Expansion, Sirolimus, Protein Structure, Quaternary
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.